Myles Wolf, M.D., M.M.Sc. has served as a member of Akebia Therapeutics' Board of Directors since April 2020 and has significant experience advising biotechnology, pharmaceutical and diagnostic firms on strategy, target identification and clinical drug development. Since 2024 he has served as the Sanford I. Weill Professor and Chair of Medicine at Weill Cornell Medicine and as Physician-in-Chief at New York Presbyterian Hospital. From 2016 to 2024 he was Chief of the Division of Nephrology and Charles Johnson, MD Professor of Medicine at Duke University School of Medicine. His patient-oriented, epidemiological and basic laboratory research focuses on disordered mineral metabolism across the spectrum of chronic kidney disease.